Status: Recruiting
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Participants needed: 292
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Bicara TherapeuticsUpdated: Aug 15, 2025Locations: 20
Eligibility criteria
Patient must have measurable disease amendable to biopsy and be willing to under... [+5]
For Part A: Exposure to anti-EGFR antibodies within 4 weeks of the first dose of... [+8]